

Octavio Ballesta-LÃ³pez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5002531/publications.pdf>

Version: 2024-02-01

11
papers

103
citations

1684188

5
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

143
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Annals of Hematology, 2020, 99, 1989-2007.	1.8	26
2	<p>IDH1-mutated relapsed or refractory AML: current challenges and future prospects</p>. Blood and Lymphatic Cancer: Targets and Therapy, 2019, Volume 9, 19-32.	2.7	24
3	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. Blood Reviews, 2020, 44, 100675.	5.7	23
4	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 659-668.	1.3	10
5	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. European Journal of Hospital Pharmacy, 2022, 29, e41-e45.	1.1	9
6	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. Expert Opinion on Emerging Drugs, 2022, 27, 1-18.	2.4	7
7	Extracorporeal photopheresis vs standard therapies for steroidâ€refractory chronic graftâ€vsâ€host disease: Pharmacoeconomic assessment of hospital resource use in Spain. Journal of Clinical Apheresis, 2021, 36, 612-620.	1.3	2
8	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. European Journal of Haematology, 2021, 106, 724-733.	2.2	1
9	Healthcare Resource Utilization among Patients between 60â€75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. Cancers, 2022, 14, 1921.	3.7	1
10	Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study. Journal of Oncology Pharmacy Practice, 2021, 27, 268-278.	0.9	0
11	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Future Oncology, 2021, 17, 215-227.	2.4	0